Tonix Pharmaceut Stock Price, News & Analysis

Tonix Pharmaceuticals (Nasdaq: TNXP) announced its inclusion in the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective June 30, 2025. This addition comes as part of the 2025 Russell indexes reconstitution, which captures the 4,000 largest US stocks based on market capitalization rankings as of April 30.

The company is currently awaiting an FDA decision on TNX-102 SL for fibromyalgia management, with a PDUFA date of August 15, 2025. The FDA has granted Fast Track designation for this candidate. Additionally, Tonix has secured a contract worth up to $34 million over five years with the U.S. DoD's Defense Threat Reduction Agency for TNX-4200, a broad-spectrum antiviral agent.

Tonix's commercial subsidiary, Tonix Medicines, currently markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment. The company's development portfolio includes various candidates targeting CNS disorders, immunology, and infectious diseases, with a state-of-the-art infectious disease research facility in Frederick, Md.

Tonix Pharmaceuticals presented data at EULAR 2025 for TNX-102 SL, their novel sublingual cyclobenzaprine formulation for fibromyalgia treatment. The drug demonstrated statistically significant pain reduction in two Phase 3 studies, with a FDA PDUFA date set for August 15, 2025. TNX-102 SL is designed for bedtime dosing and transmucosal delivery, showing durable activity over 14 weeks. The drug maintains higher cyclobenzaprine levels during sleep compared to norcyclobenzaprine, unlike oral formulations. If approved, TNX-102 SL would be the first new fibromyalgia treatment in 15 years and the first in a new class of non-opioid analgesics, potentially offering an alternative to addictive opioids currently prescribed for chronic pain.

Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed James "Jim" Hunter to its Board of Directors, effective June 12, 2025. Hunter, who previously served as Executive Vice President of Commercial at Tonix, brings over 40 years of biopharmaceutical industry experience. His appointment comes at a crucial time as Tonix prepares for the potential launch of TNX-102 SL for fibromyalgia, with a PDUFA date of August 15, 2025. Hunter was instrumental in building Tonix Medicines and executing the company's entry into the migraine market. His experience includes leadership roles at Validus Pharmaceuticals, where he managed over two dozen product acquisitions, and Novartis Pharmaceuticals, where he led neuroscience sales. The appointment strengthens Tonix's commercial strategy as they expand their commercial footprint and prepare for the potential fibromyalgia drug launch.

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that CEO Seth Lederman will present at the 2025 BIO International Convention in Boston on June 16, 2025. The company is a fully-integrated biotech focused on pain management and vaccines, with its lead candidate TNX-102 SL for fibromyalgia currently under FDA review with a PDUFA date of August 15, 2025. The company's portfolio includes TNX-1500 for organ transplant rejection, TNX-801 for mpox/smallpox vaccines, and TNX-4200, supported by a $34M DoD contract. Tonix Medicines, their commercial subsidiary, markets Zembrace SymTouch and Tosymra for acute migraine treatment. The company operates an infectious disease research facility in Frederick, MD.

Tonix Pharmaceuticals (NASDAQ: TNXP) announced a poster presentation at EULAR 2025 in Barcelona, focusing on their TNX-102 SL treatment for fibromyalgia. The presentation, scheduled for June 13, 2025, will discuss how the transmucosal sublingual cyclobenzaprine targets non-restorative sleep and provides sustained pain reduction. Notably, TNX-102 SL has received Fast Track designation from the FDA, with a PDUFA date set for August 15, 2025. The company's pipeline includes TNX-1500 for organ transplant rejection and autoimmune diseases, TNX-801 for mpox/smallpox vaccines, and TNX-4200, supported by a $34M DoD contract. Tonix also markets migraine treatments Zembrace SymTouch and Tosymra through its commercial subsidiary.

Tonix Pharmaceuticals (NASDAQ: TNXP) has initiated dosing in the Phase 2 OASIS study evaluating TNX-102 SL for reducing acute stress reaction (ASR) severity and acute stress disorder (ASD) frequency. The investigator-initiated trial, sponsored by the University of North Carolina and supported by a $3 million DoD grant, will enroll approximately 180 motor vehicle collision survivors. The study will randomize participants to receive either TNX-102 SL 5.6 mg or placebo for two weeks. The trial builds on TNX-102 SL's previous success in improving sleep quality in PTSD patients. The study leverages UNC's $40 million AURORA initiative infrastructure and aims to address a significant unmet need, as no medication currently exists for immediate post-trauma treatment. Topline results are expected in the second half of 2026.

Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed Joseph Hand, Esq. as General Counsel and Executive Vice President of Operations. Hand brings over 20 years of strategic legal and business leadership experience, including a notable tenure at Celgene Corporation where he served on the Executive Committee. His role was crucial in the $74 billion Bristol Myers Squibb acquisition of Celgene and the $13.4 billion Otezla divestiture to Amgen. This appointment comes at a critical time as Tonix awaits potential FDA approval for TNX-102 SL for fibromyalgia management, with a PDUFA date of August 15, 2025. Hand's most recent position was Chief Administrative Officer at Phathom Pharmaceuticals, where he led the recruitment of over 300 employees. The company is currently developing several key products, including TNX-1500 for organ transplant rejection and TNX-801, a vaccine for mpox.

Tonix Pharmaceuticals (TNXP) reported Q1 2025 financial results and operational highlights. The company's lead candidate TNX-102 SL for fibromyalgia has a PDUFA date of August 15, 2025. If approved, it would be the first new fibromyalgia drug in over 15 years. The company reported $131.7 million in cash, sufficient to fund operations into Q2 2026. Key highlights include positive Phase 1 results for TNX-1500 for kidney transplant rejection prevention and progress with TNX-801 vaccine for mpox. Q1 financial results showed net product revenue of $2.4 million, R&D expenses of $7.4 million, and a net loss of $16.8 million ($2.84 per share). The company raised additional funds through ATM sales, generating $59.8 million in Q1 and $9.9 million subsequently.

Tonix Pharmaceuticals presented promising preclinical data for gastric cancer treatment at the AACR 2025 Annual Meeting in Chicago. The research focused on a combination therapy using TFF2 with anti-PD1 antibody, showing positive results in activating cancer-killing CD8+ T cells.

The study demonstrated that TFF2-MSA, when combined with anti-PD1 antibody, effectively reduces immunosuppression in the tumor microenvironment. The company is developing TNX-1700 (TFF2-HAS) as their lead immuno-oncology program.

Key findings revealed that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. The research also identified a potential negative correlation between TFF2 and PMN-MDSCs levels in gastric cancer patients, suggesting therapeutic potential for treating gastric and colorectal cancers.